Biogen Idec news from FiercePharma
NewsTysabri to get new Euro label
The European Medicines Agency called for an update to product information for Biogen Idec and Elan's multiple sclerosis drug Tysabri, highlighting the risk of a potentially deadly brain infection.... Read more...
Tysabri may deliver 'sustained improvement'
Tysabri may have scored a big plus for drugmakers Biogen Idec and Elan. A trial of the multiple sclerosis treatment showed that it might... Read more...
FDA, Biogen mull Tysabri label changes
The FDA is huddling with Biogen Idec and Elan on amendments to Tysabri's label. The reason, of course, is the
Icahn snaps up more of Biogen
The Biogen Idec faithful have been preaching "buying opportunity" ever since the company announced two new... Read more...
Analysts: Tysabri scrips will suffer
When Biogen Idec announced last week that a potentially fatal brain infection had cropped up again in Tysabri... Read more...
Biogen: Tysabri patients have PML
Biogen Idec CEO James Mullen predicted it, and now it's happened: Two Tysabri patients have come down with the potentially fatal brain infection, progressive multifocal leukoencephalopathy, or PML,... Read more...
Earnings up, earnings down for drugmakers
A plethora of drug-and-device results today, from falling profits at Boston Scientific and Schering-Plough to higher earnings and flat sales at Merck. Here's the roundup:
Merck posted net income of... Read more...
Biogen CEO: Tysabri to reach $1B in 2008
Two years ago this week, Biogen Idec relaunched Tysabri, the multiple sclerosis and Crohn's disease treatment, after a safety scare. Now, the drug is shaping up to be a blockbuster, the Wall Street... Read more...
Biogen, Icahn trade insults via the SEC
Remember when shareholder Carl Icahn bullied Biogen Idec into putting itself on the block last year? The company entertained offers but ended up saying, "No deal." Now, Icahn and Biogen are trading... Read more...
SPOTLIGHT: Rituxan falls short in lupus trial
In a big disappointment for Genentech and Biogen Idec, Rituxan failed its late-stage test against lupus. Already approved for non-Hodgkins lymphoma and rheumatoid arthritis treatment, Rituxan might... Read more...
| Press ReleasesEU Panel Recommends Update For Elan, Biogen's Tysabri LabelEU Panel Recommends Update For Elan, Biogen's Tysabri Label ZURICH -(Dow Jones)- European Medicines Agency, an advisory body to the European drugs regulator, said Thursday it recommends an update of Read more >> First Multiple Myeloma Patient TreatedElan and Biogen Idec Initiate First Clinical Trial of TYSABRI® in Oncology First Multiple Myeloma Patient Treated CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--Sept. 5, 2008--Elan Read more >> Biogen Idec Announces First Startup in Its Innovation Incubator Biogen Idec Announces First Startup in Its Innovation Incubator Initiative Designed to Contribute to Productivity of Early-Stage Pipeline First Project Leverages Original Finding by Columbia Read more >> PRESS RELEASE: Biogen Idec completes Review of Strategic Alternatives BIOGEN IDEC COMPLETES REVIEW OF STRATEGIC ALTERNATIVES Company to Remain Independent Cambridge, MA, December 12, 2007 - The Board of Directors of Biogen today announced that, after completing a Read more >> PRESS RELEASE: Biogen Idec and Neurimmune Announce $380M Alliance to Develop Treatments for Alzheimer's Diseases Biogen Idec and Neurimmune Announce $380M Alliance to Develop Treatments for Alzheimer's Diseases Cambridge, MA and Zürich, Switzerland, November 20, 2007 – Biogen Idec and Neurimmune Read more >> |
Get more Biogen Idec coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
